Peptides DB
Research-centric peptide and protocol reference hub

HCG (Human Chorionic Gonadotropin) record · updated 7h ago

Healing & recoveryMetabolic & appetiteGrade A · human clinicalResearch use only
All 16 studiesJump to the evidenceCompare
What is HCG (Human Chorionic Gonadotropin) used for?

HCG (Human Chorionic Gonadotropin) is an FDA-approved glycoprotein hormone that mimics luteinizing hormone, used to stimulate endogenous testosterone production and support fertility in men and women.

How it works: LH/CG receptor agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where HCG (Human Chorionic Gonadotropin) sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 26 registered trials. It describes the research record, not a recommendation.

Identity
NameHCG (Human Chorionic Gonadotropin)
Full name—
Sequence—
ClassSexual Health
Research levelFDA Approved
Discovered byCurated master list · 2026
Pharmacology
MechanismLH/CG receptor agonist
RouteSubcutaneous injection
Half-life~24 hours
Time to peak6–24 hours
DurationVaries
Extraction confidence0.90
Effect profile · 0–5
Healing & recovery: Healing 3.0, Muscle 2.0, Metabolic 3.0, Neuro 1.0, Sleep 0.0, Immune 1.0, Skin 2.0Healing & recovery — 3.0 / 5Muscle & body comp — 2.0 / 5Metabolic & appetite — 3.0 / 5Neuro & mood — 1.0 / 5Inflammation & immune — 1.0 / 5Skin & aesthetics — 2.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin3.02.03.01.00.01.02.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies16
Human / animal / cellular11 / 4 / 0
Highest trial phasePreclinical
Years covered2026
Latest study10d ago
Publication history
20262026
Research funding
934 NIH projects · $24.7M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports12
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

16 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Male fertility is independent of Enh13 control of <i>Sox9</i> testicular expression
FindingNot reported in abstract.
Animal2026Full text read0.70
A proteomic signature of oocyte quality from models of varying oocyte developmental competence
Findinglog2FC of ± 1 and a p-value ≤ 0.05 between in vivo and in vitro maturation systems.
Animal2026Full text read0.80
Predictive Value of Day 1–4 β-hCG Change for Single-Dose Methotrexate Failure in Tubal Ectopic Pregnancy
FindingMedian day 1–4 β-hCG percentage change was +26.4% (IQR 10.9–50.8) in the failure group versus -5.9% (IQR -16.8 to +6.6) in the success group (P<0.001).
Human2026Full text read0.80
Risk factors of Intrauterine Pregnancy Loss Following Surgical of Heterotopic Pregnancy:A Retrospective Analysis of 102 Cases from a Single Center
Finding14 (13.73%) experienced miscarriage following surgical treatment, n=102.
Human2026Full text read0.80
Erzhi Tiangui formula ameliorates ovarian aging by enhancing antioxidant defense via Nrf2/HO-1 signaling.
FindingNot reported in abstract.
Animal2026Full text read0.70
Prospective, Open-Label, and Three-Arm Investigator-Initiated Study to Compare the Efficacy and Safety of Three Estradiol Treatment Protocols for Endometrial Preparation in Frozen Embryo Transfer (FET) Cycles.
FindingMean serum estradiol levels were highest with vaginal estradiol hemihydrate (701.63 pg/mL), significantly exceeding levels with oral estradiol hemihydrate (331.84 pg/mL; p=0.042).
Human2026Full text read0.80
Atypical presentation of severe ovarian hyperstimulation syndrome complicated by isolated pleural effusions: a case series and literature review.
TakeawayPleural effusion can be a rare manifestation of severe ovarian hyperstimulation syndrome, requiring prompt management and drainage for patient recovery.
Human2026Full text read0.70
ICSI shows no advantage over conventional IVF in patients with unexpected low oocyte yield.
FindingDay 3 good quality embryo rate: 59.76% IVF-LN vs 47.46% ICSI-LN; p < 0.01.
Human2026Full text read0.80
Immediate post-denudation intracytoplasmic sperm injection is associated with higher fertilization and early cleavage-stage embryo yield: a prospective sibling-oocyte cohort from Libyan ICSI cycles.
Finding80.07% ± 17.09% fertilization rate for immediate ICSI vs 70.80% ± 17.37% for delayed ICSI, mean difference: 9.26, 95% CI 4.40-14.12, p = 0.0003
Human2026Full text read0.80
Forecasting preterm birth in Kazakhstan through 2050: a cohort-component demographic modeling study.
FindingProjected preterm births stabilize at approximately 30,000-33,000 cases annually by 2050.
—2026Full text read0.70
The impact of previous history of malignant tumors/precancerous lesions on IVF/ICSI outcomes: a retrospective cohort study.
FindingConservative CLBR for malignant tumors/precancerous lesions plateaued at around 53% after four cycles, n=251.
Human2026Full text read0.90
Postoperative stimulated thyroglobulin and the ps-tg/TSH ratio enhance the 2025 ATA risk stratification for predicting radioiodine response in papillary thyroid carcinoma.
FindingAUC 0.862 for Model 1 vs. AUC 0.614 for Model 2.
Human2026Full text read0.80

Articles mentioning HCG (Human Chorionic Gonadotropin)